TenQ · fact sheet · filings current to · price as of
Moderna (MRNA)
The business itself is the question here - 11 of 36 checks passed.
Latest close : $145.55, -2.2% on the day; -16.5% from the 52-week high. Refreshed every trading night.
Full analysis: report · all charts. Financial statements are computed from SEC EDGAR XBRL filings, current to . The share price and everything built on it (market cap, multiples, yields, the Value and Trend checks) are refreshed every trading night; this page shows the close of . Not investment advice.
Key figures
| Share price (delayed close) | $145.55 |
| Market cap | $58.1B |
| 52-week range | $22.36 - $174.38 |
| P/E | - |
| P/E, own 2-year median | - |
| P/S | 26.1x |
| Free cash flow yield | -2.1% |
| Dividend yield | - |
| Revenue (TTM) | $2.2B |
| Net income (TTM) | $-3.2B |
| Free cash flow (TTM) | $-1.2B |
| Gross margin | 23.4% |
| Operating margin | -149.0% |
| Return on equity | -46.6% |
| Revenue growth (1y) | -27.6% |
| Revenue CAGR (3y) | -53.4% |
| Debt / equity | 0.09x |
| Cash & short-term investments | $1.7B |
| Shares outstanding | 399.2m (cover page of the latest filing, 2026-07-24) |
The score: 11 of 36 checks passed
Six chapters, six pass/fail checks each. Five are computed from the filings; Trend is price behaviour, and says so.
Is MRNA stock cheap or expensive right now?
Value · 0 of 6 checks passed. Expensive against its own history and its sector (judged on sales - not yet profitable) - you're paying up for what you get. chapter →
Is Moderna still growing?
Growth · 1 of 6 checks passed. Growth is weak or inconsistent - the trend, not the story, is the problem. chapter →
Does Moderna make real money?
Quality · 0 of 6 checks passed. Profitability is thin or negative - the growth isn't turning into money yet. chapter →
Can Moderna survive a bad year?
Health · 3 of 6 checks passed. Financially sound overall, with one or two things worth watching. chapter →
What does Moderna hand back to shareholders?
Shareholder returns · 1 of 6 checks passed. What comes back to owners is thin or stretched - read the checks before counting on it. chapter →
Which way is MRNA trending?
Trend analysis · 6 of 6 checks passed. The market agrees: the stock is in a healthy uptrend on every horizon. chapter →
Are insiders buying or selling MRNA?
Open-market buys: $0.00 · sells: $36M, across the recent Form 4 filings. detail →
Other pharma and chemicals we cover: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · Procter & Gamble (PG) · Amgen (AMGN) · every company →
Method: figures computed deterministically from SEC EDGAR XBRL (companyfacts, frames, financial-statement-and-notes datasets, Form 4); prices delayed end-of-day. Scores count transparent pass/fail checks. Missing data is shown as missing, never estimated. Last changed . © TenQ - cite with a link to this page.